| scholarly article | Q13442814 |
| P50 | author | Donald Morton | Q16019759 |
| P2093 | author name string | Atsushi Tanemura | |
| Dave S B Hoon | |||
| Myung-Shin Sim | |||
| Anneke Q van Hoesel | |||
| Michiel F G de Maat | |||
| Alicia M Terando | |||
| P2860 | cites work | GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer | Q24648331 |
| CpG island methylator phenotype in colorectal cancer | Q24672170 | ||
| Cancer statistics, 2007 | Q29547293 | ||
| Gene silencing in cancer in association with promoter hypermethylation | Q29617274 | ||
| MethPrimer: designing primers for methylation PCRs | Q29618664 | ||
| Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. | Q33796956 | ||
| Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma | Q34086791 | ||
| Hypermethylation of the GATA genes in lung cancer | Q34374470 | ||
| Synthesis of universal unmethylated control DNA by nested whole genome amplification with phi29 DNA polymerase. | Q34396042 | ||
| Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. | Q34432769 | ||
| Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway | Q34486845 | ||
| The role of tissue factor pathway inhibitor-2 in cancer biology | Q37000486 | ||
| Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles | Q38432389 | ||
| Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients | Q40082103 | ||
| Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth | Q40138689 | ||
| Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. | Q40156793 | ||
| Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma | Q42488421 | ||
| Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. | Q42596171 | ||
| CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer | Q44545555 | ||
| Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer | Q44980772 | ||
| Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus | Q45419139 | ||
| Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. | Q46696080 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | CpG island | Q1138360 |
| phenotype | Q104053 | ||
| P304 | page(s) | 1801-1807 | |
| P577 | publication date | 2009-02-17 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | CpG island methylator phenotype predicts progression of malignant melanoma | |
| P478 | volume | 15 |
| Q36010918 | A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis |
| Q35962455 | AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome |
| Q34516587 | Aberrant DNA methylation in malignant melanoma |
| Q37737945 | Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities. |
| Q35989635 | Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma |
| Q53281416 | Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis. |
| Q36355891 | Analysis of the molecular features of rectal carcinoid tumors to identify new biomarkers that predict biological malignancy |
| Q33842160 | Application of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view |
| Q33689442 | Array-Based DNA Methylation Profiling for Breast Cancer Subtype Discrimination |
| Q34709370 | Assessment of DNA methylation status in early stages of breast cancer development |
| Q35550888 | Biomarkers as key contributors in treating malignant melanoma metastases |
| Q35023463 | Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome |
| Q35909621 | Clinical utility of RASSF1A methylation in human malignancies |
| Q48215153 | Comparative analysis of DNA methylation patterns of equine sarcoid and healthy skin samples. |
| Q45889426 | Correlation of CpG island methylator phenotype with poor prognosis in hepatocellular carcinoma |
| Q35611238 | CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis |
| Q36351328 | CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. |
| Q40803117 | DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients |
| Q34359695 | DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations |
| Q37961789 | DNA methylation and miRNA expression profiling in childhood B-cell acute lymphoblastic leukemia. |
| Q34416046 | DNA methylation profiles in primary cutaneous melanomas are associated with clinically significant pathologic features. |
| Q35667377 | DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses |
| Q35834765 | DNA methylation subgroups in melanoma are associated with proliferative and immunological processes |
| Q47119104 | DNA methylation/hydroxymethylation in melanoma |
| Q34775571 | DNA-methylation profiling distinguishes malignant melanomas from benign nevi |
| Q61447666 | Demethylation by low-dose 5-aza-2'-deoxycytidine impairs 3D melanoma invasion partially through miR-199a-3p expression revealing the role of this miR in melanoma |
| Q34254446 | Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma |
| Q36041771 | Dissecting DNA hypermethylation in cancer. |
| Q87424385 | Down-regulation of MFG-E8 by RNA interference combined with doxorubicin triggers melanoma destruction |
| Q34713622 | Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma |
| Q90733821 | Dual-functionality of RASSF1A overexpression in A375 cells is mediated by activation of IL-6/STAT3 regulatory loop |
| Q28087759 | Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer |
| Q37798947 | Epigenetic Alterations as Cancer Diagnostic, Prognostic, and Predictive Biomarkers |
| Q38847201 | Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF-κB Pathway in Melanoma. |
| Q34283143 | Epigenetic alterations in metastatic cutaneous carcinoma. |
| Q36080974 | Epigenetic biomarkers in skin cancer |
| Q38125641 | Epigenetic cancer prevention mechanisms in skin cancer |
| Q37800011 | Epigenetic modifications as therapeutic targets |
| Q41742271 | Epigenetic pathogenesis of human papillomavirus in upper aerodigestive tract cancers. |
| Q28085681 | Epigenetic regulation in human melanoma: past and future |
| Q37478182 | Epigenetic regulation of REG1A and chemosensitivity of cutaneous melanoma. |
| Q26753019 | Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential |
| Q37385238 | Epigenetic status of LINE-1 predicts clinical outcome in early-stage rectal cancer. |
| Q38012175 | Epigenetics of estrogen receptor-negative primary breast cancer |
| Q33980682 | Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies |
| Q38217482 | Epigenetics of human melanoma: promises and challenges. |
| Q38148588 | Epigenetics of melanoma: implications for immune-based therapies. |
| Q37737449 | Epigenetics of ovarian cancer: from the lab to the clinic |
| Q38017604 | Epigenetics of regional lymph node metastasis in solid tumors. |
| Q37380194 | Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. |
| Q36085799 | Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations |
| Q38660042 | Epigenomic landscape of melanoma progression to brain metastasis: unexplored therapeutic alternatives. |
| Q38906998 | Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation |
| Q41122284 | Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. |
| Q36152246 | Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer |
| Q38960818 | KIT is a frequent target for epigenetic silencing in cutaneous melanoma. |
| Q38224624 | Melanoma epigenetics: novel mechanisms, markers, and medicines. |
| Q34788817 | Melanoma genotypes and phenotypes get personal |
| Q35069309 | Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients |
| Q38940120 | MiR-199a inhibits the ability of proliferation and migration by regulating CD44-Ezrin signaling in cutaneous squamous cell carcinoma cells |
| Q92646188 | MiR-659-3p regulates the progression of chronic myeloid leukemia by targeting SPHK1 |
| Q47142132 | MicroRNA in Glioblastoma: An Overview |
| Q46055814 | Molecular mechanisms of metastasis. |
| Q24289344 | Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease |
| Q34499759 | Multiparametric analysis of cell-free DNA in melanoma patients |
| Q38438819 | Native Oligodendrocytes in Astrocytomas Might Inhibit Tumor Proliferation by WIF1 Expression |
| Q91045454 | Prediction and Analysis of Skin Cancer Progression using Genomics Profiles of Patients |
| Q33647365 | Predictive value of CpG island methylator phenotype for tumor recurrence in hepatitis B virus-associated hepatocellular carcinoma following liver transplantation |
| Q36905877 | Prognostic molecular biomarkers for cutaneous malignant melanoma |
| Q27001734 | Progression of cutaneous melanoma: implications for treatment |
| Q34842139 | Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients |
| Q34843148 | RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression |
| Q38956821 | RASSF1A-LATS1 signalling stabilizes replication forks by restricting CDK2-mediated phosphorylation of BRCA2. |
| Q36557527 | RASSF8 regulates progression of cutaneous melanoma through nuclear factor-κb |
| Q26991808 | SOCS, inflammation, and cancer |
| Q39273551 | Suppressor of cytokine signaling 1 blocks mitosis in human melanoma cells. |
| Q90398519 | Targeting Epigenetic Dependencies in Solid Tumors: Evolutionary Landscape Beyond Germ Layers Origin |
| Q28075374 | The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation |
| Q34471940 | The association of RAS association domain family Protein1A (RASSF1A) methylation states and bladder cancer risk: a systematic review and meta-analysis |
| Q34277400 | The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data |
| Q36282768 | The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics |
| Q39063402 | Tumor necrosis factor-α and apoptosis induction in melanoma cells through histone modification by 3-deazaneplanocin A |
| Q36443927 | Tumor-Related Methylated Cell-Free DNA and Circulating Tumor Cells in Melanoma. |
| Q33570282 | Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis |
| Q36517507 | Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients |
| Q42722387 | miR-199a-5p induces cell invasion by suppressing E-cadherin expression in cutaneous squamous cell carcinoma |
Search more.